Skip to Content

Daliresp (roflumilast) Disease Interactions

There is 1 disease interaction with Daliresp (roflumilast):


Roflumilast (Includes Daliresp) ↔ Hepatic Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Roflumilast is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). Roflumilast is extensively metabolized via Phase I (cytochrome P450) and Phase II (conjugation) reactions. Clinicians should consider the risk-benefit of administering roflumilast to patients with mild liver impairment (Child-Pugh A).

Daliresp (roflumilast) drug Interactions

There are 277 drug interactions with Daliresp (roflumilast)

Daliresp (roflumilast) alcohol/food Interactions

There is 1 alcohol/food interaction with Daliresp (roflumilast)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.